Donate
A review explains two lysine-breakdown routes in the body and argues that reducing flux through the saccharopine pathway could be therapeutic for PDE-ALDH7A1 and related disorders.
Lysine is an essential amino acid, but the body must carefully break it down. Two pathways are discussed in this review: the saccharopine pathway and the pipecolate pathway. Recent research has suggested the saccharopine pathway may play a bigger role in brain lysine metabolism than previously appreciated.
The review focuses on AASS, a bifunctional enzyme with a lysine alpha-ketoglutarate reductase (LKR) domain and a saccharopine dehydrogenase (SDH) domain. In PDE-ALDH7A1, the downstream enzyme that should convert alpha-AASA onward is deficient, so alpha-AASA and P6C accumulate, and P6C can bind PLP and disrupt synaptic chemistry.
The key therapy idea discussed is “substrate reduction”: if you partially downregulate LKR/AASS, you may reduce the metabolic flow into the toxic bottleneck. The review also places PDE in a broader context of saccharopine-pathway diseases (including hyperlysinemias and glutaric aciduria type I), arguing that pathway-aware interventions could be a rational way to reduce neurotoxic metabolite exposure without eliminating lysine entirely.
Why this matters
It’s a helpful scientific map for families and advocates: it shows where PDE sits in lysine metabolism and why upstream enzymes like LKR/AASS are being considered as drug targets.
Limitations
This is a review. It synthesizes evidence and proposes therapeutic logic but does not itself demonstrate clinical benefit.
Sources
- “Lysine alpha-ketoglutarate reductase as a therapeutic target for saccharopine pathway related diseases.” Frontiers in Molecular Neuroscience (2025). DOI: 10.3389/fnmol.2025.1695490 (PubMed: 41194801; Free full text: PMC12583054)
Safety note: This summary is educational and not medical advice.
